These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26590026)

  • 1. Excellent response to levetiracetam in epilepsy with Wolf-Hirschhorn syndrome.
    Karalok ZS; Arhan EP; Erdogan KM; Gurkas E
    Childs Nerv Syst; 2016 Jan; 32(1):9-11. PubMed ID: 26590026
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of migrating partial seizures in Wolf-Hirschhorn syndrome with bromide.
    Itakura A; Saito Y; Nishimura Y; Okazaki T; Ohno K; Sejima H; Yamamoto T; Maegaki Y
    Brain Dev; 2016 Aug; 38(7):658-62. PubMed ID: 26797656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Antiseizure Medications in Wolf-Hirschhorn Syndrome.
    Horiguchi A; Koichihara R; Kikuchi K; Nonoyama H; Daida A; Oba D; Hirata Y; Matsuura R; Ohashi H; Hamano SI
    Neuropediatrics; 2023 Oct; 54(5):339-343. PubMed ID: 37075791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of epilepsy and electroencephalogram patterns in Wolf-Hirschhorn syndrome: experience with 87 patients.
    Battaglia A; Filippi T; South ST; Carey JC
    Dev Med Child Neurol; 2009 May; 51(5):373-80. PubMed ID: 19379291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of levetiracetam in children with epilepsy.
    Li J; Xiao N; Chen S
    Brain Dev; 2011 Feb; 33(2):145-51. PubMed ID: 20359839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Successful treatment with levetiracetam in a case of Ohtahara syndrome caused by STXBP1 mutation].
    Yamashita S; Chiyonobu T; Yoshida M; Moroto M; Morita T; Morioka S; Kato M; Saitsu H; Morimoto M; Hosoi H
    No To Hattatsu; 2013 Jan; 45(1):64-6. PubMed ID: 23593750
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of levetiracetam in children with epilepsy younger than 2 years of age.
    Krief P; Li Kan ; Maytal J
    J Child Neurol; 2008 May; 23(5):582-4. PubMed ID: 18448575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombocytopenia as an adverse effect of levetiracetam therapy in a child.
    Peer Mohamed B; Prabhakar P
    Neuropediatrics; 2009 Oct; 40(5):243-4. PubMed ID: 20221962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conclusions of the available meta-analyses exploring the efficacy of levetiracetam.
    Tellez-Zenteno JF
    Can J Neurol Sci; 2011 May; 38(3):388-9. PubMed ID: 21515492
    [No Abstract]   [Full Text] [Related]  

  • 10. The place of levetiracetam in the treatment of epilepsy.
    Leppik IE
    Epilepsia; 2001; 42 Suppl 4():44-5. PubMed ID: 11564126
    [No Abstract]   [Full Text] [Related]  

  • 11. Distinctive EEG patterns in patients with Wolf-Hirschhorn syndrome.
    Bergemann AD
    Dev Med Child Neurol; 2009 May; 51(5):337-8. PubMed ID: 19388145
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy.
    Grosso S; Franzoni E; Coppola G; Iannetti P; Verrotti A; Cordelli DM; Marchiani V; Pascotto A; Spalice A; Acampora B; Morgese G; Balestri P
    Seizure; 2005 Jun; 14(4):248-53. PubMed ID: 15911359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy.
    Belcastro V; Pierguidi L; Tambasco N
    Brain Dev; 2011 Apr; 33(4):289-93. PubMed ID: 20630672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy.
    Li S; Cao J; Xiao N; Cai F
    J Child Neurol; 2010 May; 25(5):609-13. PubMed ID: 19779208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Levetiracetam (keppra) in epileptology].
    Kalinin VV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(3):74-7. PubMed ID: 18683359
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of physical and mental adverse drug reactions associated with levetiracetam in post-stroke epilepsy.
    Robins A; Patel M; Azim A
    J Am Geriatr Soc; 2012 Jan; 60(1):159-60. PubMed ID: 22239298
    [No Abstract]   [Full Text] [Related]  

  • 17. Levetiracetam for the treatment of epilepsy among adults with intellectual disabilities.
    Deb S; Kaur Saini ST
    J Intellect Disabil Res; 2007 Jul; 51(Pt 7):564-5. PubMed ID: 17537170
    [No Abstract]   [Full Text] [Related]  

  • 18. Rapid effect of levetiracetam in a case of juvenile myoclonic epilepsy.
    Belcastro V; Costa C; Galletti F; Rossi A; Tambasco N; Striano P
    Epilepsy Behav; 2009 Jan; 14(1):269-70. PubMed ID: 18804185
    [No Abstract]   [Full Text] [Related]  

  • 19. [The value of levetiracetam in epileptic status].
    Pastor-Milán E; González-Torres V; Vilches R
    Rev Neurol; 2005 Oct 16-31; 41(8):508-9. PubMed ID: 16224741
    [No Abstract]   [Full Text] [Related]  

  • 20. No kinetic interaction between levetiracetam and cyclosporine: a case report.
    Franzoni E; Sarajlija J; Garone C; Malaspina E; Marchiani V
    J Child Neurol; 2007 Apr; 22(4):440-2. PubMed ID: 17621525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.